FindTrial
Sign In

Correlation of O6-Methyl(Alkyl) Guanine-DNA Methyl(Alkyl) Transferase (MGMT/AGAT) Gene Polymorphisms witH Blood Toxicity of Temozolomide in Adult Diffuse Glioma

Correlation of O6-Methyl(Alkyl) Guanine-DNA Methyl(Alkyl) Transferase (MGMT/AGAT) Gene Polymorphisms with Hematological Toxicity of Temozolomide in Adult Diffuse Glioma (MAGENTA study) - MAGENTA study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/07/026317
Enrollment
40
Registered
2020-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C719- Malignant neoplasm of brain, unspecified

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age over 18 years at time of index diagnosis. 2. Newly-diagnosed diffuse glioma (grade II-IV) being treated or previously treated with RT+TMZ who develop or have developed significant hematologic toxicity defined as >=grade II thrombocytopenia and >=grade III neutropenia) as per CTCAE criteria v5.0 3. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Recurrent/progressive glioma treated with salvage systemic therapies 2. Patient with a previous history of severe myelosuppression due to other cause

Design outcomes

Primary

MeasureTime frame
to test the correlation between haematological toxicity caused by Temozolomide and MGMT SNPs L84F (rs12917), I143V (rs2308321), K178R(rs2308327) in Peripheral blood mononuclear cell in diffuse glioma patients treated with TMZ.Timepoint: 6 months—

Secondary

MeasureTime frame
Not applicableTimepoint: Not applicable—

Countries

India

Contacts

Public ContactDr Tejpal Gupta

Tata Memorial Hospital

tejpalgupta@rediffmail.com02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026